Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13994892 | 0.88 | USP2 (0.37) | KMT2AAPEX1ALDH1A1LMNASLC6A9 | |
| Bromide SCHEMBL5563404 | 0.76 | GAA (0.35) | ALDH1A1 | |
| SCHEMBL10123555 | 0.76 | ALDH1A1 (0.40) | KMT2AAPEX1ALDH1A1MAPTMEN1 | |
| SCHEMBL17870725 | 0.72 | GAA (0.47) | KMT2AAPEX1MEN1SLC6A9KDM4E | |
| SCHEMBL3590708 | 0.66 | ALDH1A1 (0.43) | KMT2AAPEX1ALDH1A1MAPTMEN1 | |
| SCHEMBL3581778 | 0.66 | ALDH1A1 (0.43) | KMT2AAPEX1ALDH1A1MAPTMEN1 | |
| SCHEMBL1280773 | 0.66 | TSHR (0.56) | KMT2AAPEX1ALDH1A1MAPTMEN1 | |
| SCHEMBL27771722 | 0.65 | PTGDR2 (0.55) | KMT2AAPEX1ALDH1A1MAPTCA12 | |
| SCHEMBL6198182 | 0.64 | KMT2A (0.42) | KMT2AAPEX1ALDH1A1MAPTMEN1 | |
| SCHEMBL11538981 | 0.64 | GAA (0.43) | KMT2AALDH1A1MAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1915355-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018459-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | KMT2A 3556/4885APEX1 4765/4885ALDH1A1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.